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Abstract:  
 
Osmolytes have been proposed as treatments for neurodegenerative proteinopathies 
including Alzheimer’s disease. However, for osmolytes to reach the clinic their 
efficacy must be improved. In this work, copper(I)-catalyzed azide-alkyne 
cycloaddition chemistry was used to synthesize glycoclusters bearing six copies of 
trehalose, lactose, galactose or glucose, with the aim of improving the potency of 
these osmolytes via multivalency. A trehalose glycocluster was found to be superior 
to monomeric trehalose in its ability to retard the formation of amyloid-beta peptide 
40 (Aβ40) fibrils and protect neurons from Aβ40-induced cell death. 
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Alzheimer’s disease (AD) is the most common neurodegenerative disorder and the 
leading cause of dementia.
1
 Currently, only symptomatic treatments are available and 
there is an urgent need for a disease-modifying drug.
2
 According to the modified 
amyloid cascade hypothesis,
3
 AD is caused by small, soluble aggregates of amyloid-
beta peptide (Aβ) which are highly neurotoxic.4 It follows that one strategy to combat 
AD is to minimize the exposure of neurons to these aggregates and approaches to 
achieve this include: a) inhibiting the production of Aβ;5,6 b) inhibiting Aβ 
aggregation;
7
 c) promoting off-pathway aggregation that produces non-toxic Aβ 
aggregates;
8
 and d) improving clearance of Aβ.9,10 
 
Recently, osmolytes have been proposed as treatments for neurodegenerative 
proteinopathies including AD.
11
 Osmolytes are small organic molecules that protect 
intracellular macromolecules from denaturation caused by environmental stresses 
such as perturbing solutes, dehydration, desiccation, extreme temperature, and high 
hydrostatic pressure.
12-14
 There are three major categories of stabilizing osmolytes: 
carbohydrates; amino acids; and methylammonium/methylsulfonium compounds.
12,13
 
Many carbohydrate osmolytes have been found both to inhibit Aβ aggregation and to 
attenuate Aβ-induced neurotoxicity. Trehalose inhibits Aβ40/42 aggregation, 
dissociates pre-formed Aβ40/42 aggregates and decreases the toxicity of Aβ40.15,16  
Similarly, polymers carrying trehalose suppress Aβ40/42 fibril formation and reduce 
Aβ40/42-induced cytotoxicity.17,18  Myo-, scyllo-, and epi-inositol stabilize a non-
fibrillar Aβ42 structure and attenuate Aβ42-induced neurotoxicity.19-21  Fructose 
inhibits fibrillogenesis of Aβ40/4222 and attenuates Aβ42-induced neurotoxicity.23 In 
many of these cases, the carbohydrate osmolytes were active at millimolar 
concentrations and for them to become viable treatments for AD their effectiveness 
must be improved.  It is well established that weak interactions between proteins and 
carbohydrates can be amplified by constructing multivalent carbohydrate ligands and 
this phenomenon is known as the “cluster glycoside effect”.24,25  However, very few 
studies have investigated whether this phenomenon applies to carbohydrate osmolyte-
Aβ interactions and then only for high MW glycopolymers.17,18  Herein we describe 
the use of copper(I)-catalyzed azide-alkyne cycloaddition (CuAAC) chemistry to 
synthesize glycoclusters bearing six copies of trehalose, lactose, galactose or glucose, 
with the aim of improving the potency of the osmolytes’ effect on Aβ secondary 
structure, aggregation, and Aβ-induced neurotoxicity. 
 
The Scheme describes the synthesis of the glycoclusters. Dipentaerythritol (1) was 
chosen as the core branching unit onto which six mono- or disaccharides were 
grafted. Hexa-alkyne 2 was obtained by alkylating dipentaerythritol (1) with 
propargyl bromide under phase-transfer conditions similar to those used by Nouguier 
and McHich  to alkylate pentraerythritol.
26
 An alternative synthesis of 2 adapted from 
the method used by Touaibia et al. to alkylate pentraerythritol,
27
 involving reaction of 
dipentaerythritol (1) with propargyl bromide in DMF/KOH, was inferior (6% yield) to 
the phase-transfer method (33% yield). Peracetylated β-glucosyl azide 3 and 
peracetylated β-galactosyl azide 4 were prepared from the corresponding 1,2,3,4,6-
penta-O-acetyl-β-D-glycopyranoses by treatment with with 33% HBr in AcOH to 
form the 2,3,4,6-tetra-O-acetyl-α-D-glycopyranosyl bromides, followed by immediate 
nucleophilic displacement with NaN3 in a phase-transfer reaction according to the 
method of Tropper et al.
28
 Peracetylated β-lactosyl azide 5 was synthesized by first 
acetylating lactose with Ac2O/NaOAc and recrystallizing the crude product from hot 
MeOH to give 1,2,3,6-tetra-O-acetyl-4-O-(2,3,4,6-tetra-O-acetyl-β-D-
  
 
galactopyranosyl)-β-D-glucopyranose.29 This compound was converted to 2,3,6-tri-O-
acetyl-4-O-(2,3,4,6-tetra-O-acetyl-β-D-galactopyranosyl)-α-D-glucopyranosyl 
bromide by treatment with 33% HBr in AcOH, followed by immediate reaction with 
NaN3 in DMF to afford azide 5.
30
  Peracetylated 6-azido-6-deoxy trehalose 6 was 
prepared from trehalose which was iodinated with Ph3P/I2 followed by immediate 
acetylation with Ac2O/pyridine to form 1-O-(2,3,4,6-tetra-O-acetyl-α-D-
glucopyranosyl)-2,3,4-tri-O-acetyl-6-deoxy-6-iodo-α-D-glucopyranoside.18 This 
compound was then reacted with NaN3 in DMF to obtain azide 6.
18
  Azides 3-6 were 
“clicked” onto hexa-alkyne 2 by a CuAAC reaction31,32 followed by Zemplén 
deacetylation
33
 to afford the target glycoclusters 7–10. 
 
The effect of glycoclusters 7–10 on Aβ40 aggregation kinetics, secondary structure, 
fibril morphology and neurotoxicity was evaluated using the thioflavin T (ThT) 
fluorescence assay, circular dichroism (CD) spectroscopy, transmission electron 
microscopy (TEM), and the cell-based trypan blue dye exclusion assay. Control 
glucose, galactose, lactose, and trehalose were tested at concentrations six times 
greater than the glycoclusters (7–10) to ensure an equivalent concentration of mono- 
and disaccharide units. To obtain accurate and precise data from biophysical and 
biochemical experiments using Aβ, it is important to remove aggregates and prepare 
monomer-rich starting solutions of Aβ, commonly referred to as low molecular 
weight (LMW) Aβ.34,35 However, the high tendency of Aβ to aggregate makes this a 
challenging task.
35
 In this study, LMW Aβ40 was prepared by a facile procedure 
involving dissolution of Aβ40 in dilute aqueous NaOH solution (pH 10.5–12)35 
followed by dilution in phosphate buffer (pH 7.4), sonication for 60 s, and 
ultracentrifugation (80000 rpm for 90 min at 4ºC). As described below, the 
supernatant obtained from this procedure exhibited properties consistent with LMW 
Aβ including a sigmoidal kinetic growth curve with a long lag phase. 
 
Glycoclusters 7–10 were screened for their effect on Aβ40 aggregation using a 
continuous ThT assay under quiescent conditions at pH 7.4 and 37 C. ThT undergoes 
a large enhancement of its fluorescence emission upon binding to amyloid fibrils 
hence ThT fluorescence can be used to monitor Aβ aggregation.36,37 A concentration 
range of 10 nM to 100 µM of glycocluster was chosen for screening because these 
concentrations might enable identification of potent compounds that are amenable to 
drug development. Aβ40 (35 µM) exhibited a sigmoidal kinetic growth curve (Figure 
1) consistent with an autocatalytic process in which new oligomers initially form only 
via slow primary nucleation, and after elongation produces fibrils, fast fibril-catalyzed 
secondary nucleation commences and combines with elongation to generate new 
fibrils.
38,39
 This autocatalytic positive feedback loop results in exponential growth and 
secondary nucleation dominating primary nucleation as the main source of new 
oligomers.
38,39
 An empirical sigmoidal model was fitted to each of the fluorescence 
intensity versus time data sets and the amplitude and lag time were estimated.
40
 
Figure 2 shows the average results of four independent experiments.  All of the 
compounds extended the lag phase of Aβ40 aggregation with a concentration-
dependent increase in lag time observed for most compounds. In general, 
glycoclusters (7–10) at the two highest concentrations (10 µM and 100 µM) extended 
the lag phase more than the corresponding mono- and disaccharides (60 µM and 600 
µM), and all of the glycoclusters (7–10) exhibited statistically significant activity at 
100 µM with lag times increased by between 28% and 53%. Three instances of 
statistically significant changes in the amplitude of Aβ40 aggregation were observed, 
  
 
however the differences were only small (~10%). Generally, the compounds did not 
effect the amplitude (Figure 1 and Figure 2), indicating that ultimately the same 
amount of fibrils is present at equilibrium.
41
  
 
The extension of the lag phase of Aβ40 aggregation caused by trehalose glycocluster 
10 was clearly concentration-dependent, and 100 µM of 10 resulted in an extremely 
significant (p < 0.0001) 45% increase in lag time (Figure 1 and Figure 2), 
consequently trehalose glycocluster 10 was chosen for further investigation. Figure 1 
demonstrates that the lag phase of Aβ40 aggregation is extended as the concentration 
of 10 increases from 1 to 100 µM; the slope of the curve, however, remains constant. 
Hence, once the concentration of fibrils reaches a threshold level, the rate of fibril 
formation is the same and independent of the lag time.
42
 Although the lag time and 
slope are each determined by both nucleation and growth processes,
41
 the 
combination of an increase in lag time with no change in slope suggests that trehalose 
glycocluster 10 inhibits the rate of primary nucleation, with no or only a minor effect 
on secondary nucleation and elongation.
42
  
 
CD spectroscopy was used to confirm the results of the ThT assay and to determine 
the secondary structure of the aggregates.  This technique relies on the well-
established principle that LMW Aβ with predominantly unordered structure43 
transitions to β-sheet rich aggregates,34,44 and it has previously been used to study 
inhibition of Aβ aggregation.45 Trehalose glycocluster 10 was incubated with Aβ40 at 
molar ratios of 1:5, 1:1 and 5:1 under quiescent conditions at pH 7.4 and 37 C. The 
CD spectra were recorded over the wavelength range 190–250 nm and deconvoluted 
using the CONTIN algorithm
46,47
 on the DICHROWEB server.
48
 Table 1 shows the 
percentage of each secondary structural motif at 0 and 72 h for each sample. Initially, 
Aβ40 had primarily (82–87%) unordered secondary structure with negligible (0–3%) 
β-structure (β-sheet and β-turn) and a small (11–15%) -helical component. These 
results are consistent with previous studies, which showed that LMW Aβ lacks 
significant ordered structure, and that transient -helix-containing intermediates occur 
“on-pathway” to the formation of β-structure rich fibrils.34,44 After 72 h, the Aβ40 
control sample transitioned to predominantly (70%) β-structure with only small 
unordered (12%) and -helical (18%) components, consistent with prior studies.34,44  
Trehalose had little effect on the β-structure content (65–69%), and trehalose 
glycocluster 10 at the two lowest concentrations was only marginally more active 
(62% β-structure). However, the sample containing trehalose glycocluster 10 at a ratio 
of 5:1 (10:Aβ40) displayed substantially less β-structure content (42%) and more 
unordered (36%) and -helical (22%) secondary structure compared to Aβ40 control. 
This confirms the results of the ThT assay, that trehalose glycocluster 10 delays but 
does not prevent the eventual formation of Aβ40 fibrils that are rich in β-structure. 
 
The morphology of the Aβ40 fibrils at equilibrium was studied using TEM. Trehalose 
glycocluster 10 was incubated with Aβ40 at molar ratios of 1:5, 1:1 and 5:1 under 
quiescent conditions at pH 7.4 and 37 °C for 7 days. Fibrils averaging ~12 nm in 
width and > 2 m long were observed for Aβ40 alone and when Aβ40 was incubated 
with trehalose (Figure 3). Trehalose glycocluster 10 had a subtle effect on the fibril 
morphology, with slightly smaller average fibril width (~9 nm) and a significant 
number of shorter (< 2 m) fibrils observed, and this effect was most pronounced in 
the sample containing the highest concentration of 10 (Figure 3). Taken together, the 
results of the ThT, CD and TEM studies reveal that the principal effect of trehalose 
  
 
glycocluster 10 is inhibition of the rate of primary nucleation, with no significant 
effect on the thermodynamic equilibrium of Aβ40 aggregation.  
 
The preferential exclusion of osmolyte (preferential hydration of protein) theory 
explains the mechanism by which osmolytes protect folded proteins from 
denaturation.
49,50
 It states that osmolytes raise the Gibbs energy of the unfolded 
denatured state more than they do the folded state,
49,50
 because of unfavorable 
interactions between the osmolyte and the peptide backbone, which is much more 
exposed in the unfolded state than in the folded state.
51
 This solvophobic 
thermodynamic force, called the osmophobic effect, means that protein denaturation 
in the presence of osmolyte is more unfavorable than it is in the absence of osmolyte 
and hence osmolytes promote the folded form of the protein.
52
 High-resolution NMR 
spectroscopy showed that in aqueous solution, synthetic Aβ40 adopts a compact, 
partially folded structure in which residues 13–23 form a helix and the N- and C-
termini, which contain many bends and turns, are collapsed against the central helix.
53
 
CD spectroscopy indicates that synthetic Aβ initially has predominantly unordered 
secondary structure, and the -helical content increases with time reaching maximal 
levels of 19–32% before waning as aggregation proceeds.34,44 It is well established 
that eventually, Aβ transitions into aggregates that are rich in β-structure.34,44,54-57 In 
this study, trehalose glycocluster 10 incubated with Aβ40 at a ratio of 5:1 (10:Aβ40) 
for 72 h displayed substantially less β-structure content (42%) and more unordered 
(36%) and -helical (22%) secondary structure compared to Aβ40 control (Table 1). 
Hence, preferential exclusion of trehalose glycocluster 10 due to the osmophobic 
effect may stabilize a compact helical form of Aβ40 and retard the unfavorable 
exposure of the peptide backbone that is required for the conformational transition to 
β-structure.58 This may also inhibit the rate of primary nucleation, resulting in an 
extended lag phase (Figure 1 and Figure 2). These explanations are consistent with 
molecular dynamics simulations which showed that preferential exclusion of trehalose 
is the origin of its inhibition of Aβ40 aggregation, partly due to stabilization of 
monomers with -helical structure so that β-sheet structure is prevented.59 
Compounds that retard Aβ aggregation by stabilizing helical structure may be of 
therapeutic benefit in AD because nascent Aβ generated by -secretase cleavage of 
transmembrane protein C99 (APP672-770, also called -CTF) is likely to comprise 
substantial helical content, since residues 17–23 of Aβ arise from the C99 “N-helix” 
(APP688-694) and residues 29–40/42 of Aβ (APP700-711/713) originate from within the 
C99 helical transmembrane domain (APP700-723).
60
 
 
The effect of trehalose glycocluster 10 on Aβ40-induced neurotoxicity was studied 
using a cell-based trypan blue dye exclusion assay.
61
 Preliminary studies confirmed 
that the test compounds alone were devoid of any inherent toxicity at the 
concentrations used in this study. Trehalose glycocluster 10 was incubated with Aβ40 
for 6 h at 37 °C at molar ratios of 1:1 and 2.5:1 (10:Aβ40) prior to addition to 7–9 day 
old cultured mouse primary cortical neurons. After 48 h the cells were fixed with 
trypan blue dye and the number of alive and dead cells were counted (Figure 4). The 
normal control cell death was very low at 10% and oligomeric Aβ40-induced cell 
death was 56%.  Both trehalose glycocluster 10 and trehalose
15
 were neuroprotective 
with the greatest and most significant activity observed with 100 µM of trehalose 
glycocluster 10. The percentage of neuroprotection observed with trehalose 
glycocluster 10 at 40 µM and 100µM was 45% and 59% respectively, and with 
trehalose at 240 µM and 600 µM the neuroprotection was 39% and 55% respectively. 
  
 
The mechanism of neuroprotection may be attributed to the ability of trehalose 
glycocluster 10 to inhibit primary nucleation resulting in the formation of fewer toxic 
Aβ aggregates during the 6 h incubation period used in the study. However, trehalose 
was also neuroprotective despite trehalose not exhibiting significant activity in the 
ThT fluorescence assay and the CD spectroscopy study. Trehalose is an activator of 
autophagy
62
 and increased autophagy has been found to reduce Aβ levels and improve 
cognitive function in a mouse model of AD,
63
 therefore further work is required to 
elucidate the precise mechanism of the neuroprotection observed in this study. 
Retardation of Aβ fibril formation in combination with enhanced clearance of Aβ due 
to activation of autophagy may be beneficial in the treatment of AD.
62
  
 
In conclusion, we utilized CuAAC chemistry to synthesize glycoclusters bearing six 
copies of carbohydrate osmolytes and discovered that a trehalose glycocluster (10) is 
superior to monomeric trehalose in its ability to retard the formation of Aβ40 fibrils 
and protect neurons from Aβ40-induced cell death. This work may stimulate interest 
in the development of osmolyte analogues including multivalent molecules as 
potential treatments for neurodegenerative proteinopathies. 
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Scheme. Synthesis of the glycoclusters. a) Propargyl bromide, NaOH, TBAB, 
toluene/water, 80C, 16 h, 33% yield; b) i) Azides 3–6, CuSO4, sodium ascorbate, 
THF/water, 40C, 6–18 h,  ii) 10 mM NaOMe in MeOH, 3 h, iii) Amberlite IR-
120(H
+
), yields 56%* (7), 63%* (8), 28%** (9), 20%** (10), *purification by silica 
flash column chromatography, **purification by RP-HPLC. 
 
 
Figure 1. Aggregation of Aβ40 monitored by in situ ThT fluorescence.  Aβ40 (35 
μM) was incubated with or without trehalose glycocluster 10 in phosphate buffer (20 
mM, pH 7.4, I 0.15 M, containing 20 μM ThT and 0.007% NaN3) at 37 °C under 
quiescent conditions. Fluorescence readings (ex 440 nm, em 480 nm) were taken 
every 5 mins. Four representative kinetic traces are shown for each group. 
 
 
Figure 2. ThT assay lag times and amplitudes obtained by fitting an empirical 
sigmoidal model to the fluorescence intensity versus time data using non-linear 
regression. The dashed horizontal lines show the control Aβ40 (35 μM) value. Values 
are the mean + SE of four independent experiments with *p < 0.05, **p < 0.01, ***p 
< 0.001 and ****p < 0.0001 c.f. control. Trehalose was tested at concentrations six 
times greater than trehalose glycocluster 10 to ensure an equivalent concentration of 
trehalose units. 
 
 
Figure 3. Morphology of Aβ40 fibrils after 7 days of incubation. TEM images of: a) 
Control Aβ40 (60 M), fibril width 12.3  1.2 nm; b) Aβ40 (60 M) + trehalose 
(1800 M), fibril width 11.8  1.2 nm; and c) Aβ40 (60 M) + trehalose glycocluster 
10 (300 M), fibril width 8.7  1.1 nm. Values are the mean  SD and the scale bar 
represents 200 nm. In all of the samples the majority of the fibrils were > 2 m long 
however the sample containing trehalose glycocluster 10 (300 M) exhibited a 
significant number of shorter (< 2 m) fibrils. Trehalose was tested at concentrations 
six times greater than trehalose glycocluster 10 to ensure an equivalent concentration 
of trehalose units. 
 
 
Figure 4. The effect of trehalose glycocluster 10 and trehalose on Aβ40-induced 
death of cultured mouse primary cortical neurons. Cultures were obtained from 6 
biologically different pregnant C57BL/6 mice bearing 6–9 pups each. Aβ40 (40 µM) 
was incubated with or without test compound for 6 h at 37 °C then added to the 
neurons and after 48 h cell death was determined by the trypan blue exclusion assay. 
The values are mean + SE with *p < 0.05, **p < 0.01, and ***p < 0.001 c.f. Aβ40. 
Trehalose was tested at concentrations six times greater than trehalose glycocluster 10 
to ensure an equivalent concentration of trehalose units. 
 
  
 
   
Table 1 
Conformation of A40 determined by deconvolution of CD spectra using the 
CONTIN algorithm.  
Sample Concn 
[M] 
Time 
[h] 
-
helix 
[%] 
-
sheet 
[%] 
-
turn 
[%] 
Unordered 
[%] 
A40  30 0 13 2 0 85 
 72 18 40 30 12 
A40 (30 M) 
+ glycocluster 
10 
6 0 15 1 0 84 
 72 21 35 27 17 
30 0 13 0 0 87 
 72 20 32 30 18 
150 0 11 2 0 87 
 72 22 16 26 36 
A40  (30 M) 
+ trehalose
[a]
 
36 0 15 3 0 82 
 72 19 36 30 15 
180 0 14 3 0 83 
 72 26 36 33 5 
900 0 13 2 0 85 
 72 18 36 29 17 
[a] Trehalose was tested at concentrations six times greater than trehalose 
glycocluster 10 to ensure an equivalent concentration of trehalose units. 
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